Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Inclusion Criteria: Must be 18 to 80 years of age, at the time of signing the informed consent. With a clinical diagnosis of PN defined by all of the following: * Diagnosed by a dermatologist for at least 3 months before the screening visit. * On the worst-Itch Numeric Rating Scale (WI-NRS) ranged from 0 to 10, participants who had an average worst itch score of greater than or equal to (\>=) 7 in the 7 days prior to Day 1. * Participants who had a minimum of 20 PN lesions in total on both legs, and/or both arms and/or trunk, at screening visit and Day 1. * History of failing a 2-week course of medium-to-superpotent TCS or when TCS were not medically advisable. * Had applied a stable dose of topical emollient (moisturizer) once or twice daily for at least 5 out of the 7 consecutive days immediately before Day 1. * Was willing and abled to complete a daily symptom electronic-diary for the duration of the study. Exclusion Criteria: Participants were excluded from the study if any of the following criteria apply: * Presence of skin morbidities other than PN and mild atopic dermatitis (AD) that interfered with the assessment of the study outcomes. * PN secondary to medications. * PN secondary to medical conditions such as neuropathy or psychiatric disease. * Within 6 months before the screening visit, or documented diagnosis of moderate to severe AD from screening visit to randomization visit. * Severe concomitant illness(es) under poor control that, in the investigator's j…